Insulin-like growth factor 1 (IGF-1) and IGF-1 receptor (IGF-1R) signaling plays an important role in tumor progression in patients with certain gastrointestinal tract cancers. In addition to lowering cholesterol in serum, statins have pleiotropic effects, including anti-oxidative,
antiinflammatory or antineoplastic effects. Therefore, the present study investigated whether statins could induce the apoptosis of colon cancer cells and regulate the expression of IGF1R and its associated signaling pathways in the present study. It was demonstrated that simvastatin and pravastatin
suppressed cell proliferation and induced cell death in human HT29 cells, but simvastatin was more potent than pravastatin. Simvastatin induced apoptosis in a concentrationdependent manner. In addition, simvastatin suppressed the expression of IGF1R and inhibited the activity of phosphorylatedextracellular
signalregulated kinase (ERK)1/2 and phosphorylatedAkt activated by IGF1. Simvastatin and IGF1 each stimulated the activity of phosphorylated ERK1/2. However, simvastatin inhibited cell proliferation and IGF1 stimulated cell proliferation. Mevalonic acid and PD98059 reversed the ERK activation
and apoptosis induced by treatment with simvastatin. It was concluded that simvastatin induces the apoptosis of human colon cancer cells and inhibits IGF1induced ERK and Akt expression via the downregulation of IGF1R expression and proapoptotic ERK activation. Simvastatin may be beneficial
for the treatment of colon cancer. The present study suggested that statin may possess therapeutic potential for the treatment of colon cancer.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Division of Gastroenterology, Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University School of Medicine, Hwasung, Gyeonggi 445170, Republic of Korea
Publication date: July 1, 2016
More about this publication?
Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease.
The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites